Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Zhenquan Hu
Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
Oncotarget
Oncology
Related publications
CT-721, a Potent BCR-Abl Inhibitor, Exhibits Excellent in Vitro and in Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia
Journal of Cancer
Oncology
Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a ‘Real Time’ Quantitative RT-PCR Assay
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia
Oncotarget
Oncology
A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
The ABL Switch Control Inhibitor DCC-2036 Is Active Against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Cancer Research
Cancer Research
Oncology
Concamitant Expression of the Rare E1/A3 and B2/A3 Types of BCR/ABL Transcript in a Chronic Myeloid Leukemia (CML) Patient
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Acute Myeloid Leukemia With BCR/ABL Fusion Chimera
Indian Journal of Hematology and Blood Transfusion
Hematology
Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model
Blood
Biochemistry
Immunology
Cell Biology
Hematology